AML193_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
AML · Acute Myeloid Leukemia
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- AML
- cancer_type_detailed
- Acute Myeloid Leukemia
- subtype
- —
- cancer_type
- AML
- ccle_sample_id
- AML193_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
- synthetic_from_ccle
- true
- display_name
- AML-193
- ccle_lineage
- blood
- ccle_lineage_subtype
- AML
- ccle_lineage_sub_subtype
- M5
- oncotree_code
- AML
- cancer_type_detailed
- Acute Myeloid Leukemia
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.595
- MYC_TARGETS_V2+0.588
- E2F_TARGETS+0.475
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.475
- MYC_TARGETS_V1+0.464
- IL6_JAK_STAT3_SIGNALING+0.429
- OXIDATIVE_PHOSPHORYLATION+0.427
- INTERFERON_GAMMA_RESPONSE+0.383
- PI3K_AKT_MTOR_SIGNALING+0.378
- DNA_REPAIR+0.370
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.556
- HEDGEHOG_SIGNALING-0.359
- TGF_BETA_SIGNALING-0.337
- PROTEIN_SECRETION-0.314
- ESTROGEN_RESPONSE_EARLY-0.278
- MYOGENESIS-0.265
- NOTCH_SIGNALING-0.255
- GLYCOLYSIS-0.239
- KRAS_SIGNALING_DN-0.213
- MITOTIC_SPINDLE-0.204
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SKM1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.867 |
| 2 | TCGA-A2-A0EQ-01A-11R-A034-07 | — | C | 0.857 |
| 3 | TCGA-E2-A1II-01A-11R-A144-07 | — | E | 0.848 |
| 4 | MONOMAC6_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.846 |
| 5 | KG1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.845 |
| 6 | U937_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.843 |
| 7 | 992ce1bc-46a2-4f57-ac7a-c6368c69c67c | — | — | 0.835 |
| 8 | TCGA-EW-A6SB-01A-12R-A32P-07 | — | E | 0.835 |
| 9 | TCGA-BH-A209-01A-11R-A157-07 | — | D | 0.824 |
| 10 | SIGM5_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.823 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.595 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.588 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.475 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.475 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.464 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.429 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.427 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.383 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.378 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.370 | Idelalisib | — uncovered |
| COMPLEMENT | 0.317 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.289 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.284 | Idelalisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.195 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.146 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.101 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.096 | Inavolisib | — uncovered |
| PEROXISOME | 0.094 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.090 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.077 | Inavolisib | — uncovered |